← All Ars Pharmaceuticals, INC filings

Ars Pharmaceuticals, INC DEF 14A proxy statements

Proxy statements, covering the matters put to shareholders at the annual meeting — board elections, auditor ratification and executive pay.

NASDAQ
SPRY
Ars Pharmaceuticals, INC
DEF: ARS Pharma Schedules 2026 Annual Meeting, Highlights neffy Launch
ARS Pharmaceuticals announces its 2026 Annual Meeting of Stockholders, scheduled for June 24, 2026, and provides an update on the successful commercial launch of its needle-free epinephrine nasal spray, neffy.
NASDAQ
SPRY
Ars Pharmaceuticals, INC
DEFA14A: ARS Pharmaceuticals, Inc. Files Definitive Proxy Statement
ARS Pharmaceuticals, Inc. has filed a definitive proxy statement with the SEC.
NASDAQ
SPRY
Ars Pharmaceuticals, INC
DEF: ARS Pharmaceuticals Sets Date for 2025 Annual Stockholders Meeting
ARS Pharmaceuticals announces its 2025 Annual Meeting of Stockholders to be held virtually on June 25, 2025, to elect directors and ratify the selection of its independent accounting firm.
NASDAQ
SPRY
Ars Pharmaceuticals, INC
DEFA14A: ARS Pharmaceuticals Files Definitive Proxy Statement with SEC
ARS Pharmaceuticals has filed a definitive proxy statement with the Securities and Exchange Commission.
NASDAQ
SPRY
Ars Pharmaceuticals, INC
DEF 14A: ARS Pharmaceuticals Sets Date for 2024 Annual Stockholders Meeting
ARS Pharmaceuticals will hold its 2024 Annual Meeting of Stockholders virtually on June 20, 2024, to elect directors and ratify the selection of Ernst & Young LLP as its independent accounting firm.